JP2022530089A5 - - Google Patents

Info

Publication number
JP2022530089A5
JP2022530089A5 JP2021563185A JP2021563185A JP2022530089A5 JP 2022530089 A5 JP2022530089 A5 JP 2022530089A5 JP 2021563185 A JP2021563185 A JP 2021563185A JP 2021563185 A JP2021563185 A JP 2021563185A JP 2022530089 A5 JP2022530089 A5 JP 2022530089A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
antigen
here
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530089A (ja
JP7650819B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029929 external-priority patent/WO2020219959A1/en
Publication of JP2022530089A publication Critical patent/JP2022530089A/ja
Publication of JP2022530089A5 publication Critical patent/JP2022530089A5/ja
Application granted granted Critical
Publication of JP7650819B2 publication Critical patent/JP7650819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563185A 2019-04-24 2020-04-24 抗-cd45抗体薬物コンジュゲート及びその使用 Active JP7650819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838280P 2019-04-24 2019-04-24
US62/838,280 2019-04-24
PCT/US2020/029929 WO2020219959A1 (en) 2019-04-24 2020-04-24 Anti-cd45 antibody drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2022530089A JP2022530089A (ja) 2022-06-27
JP2022530089A5 true JP2022530089A5 (cg-RX-API-DMAC7.html) 2023-05-08
JP7650819B2 JP7650819B2 (ja) 2025-03-25

Family

ID=72940686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563185A Active JP7650819B2 (ja) 2019-04-24 2020-04-24 抗-cd45抗体薬物コンジュゲート及びその使用

Country Status (4)

Country Link
US (1) US20220175951A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958910A4 (cg-RX-API-DMAC7.html)
JP (1) JP7650819B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020219959A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
BR112018073199A2 (pt) 2016-05-11 2019-04-16 Sony Corporation corantes diméricos ou poliméricos ultrabrilhantes
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
WO2019140128A1 (en) 2018-01-12 2019-07-18 Sony Corporation Phosphoalkyl polymers comprising biologically active compounds
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
EP3769085B1 (en) 2018-03-19 2022-08-24 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
JP2024536224A (ja) * 2021-09-30 2024-10-04 ソニーグループ株式会社 がん処置用のピロロベンゾジアゼピンコンジュゲート
WO2023183927A2 (en) 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
CA3016901C (en) * 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
AU2019370367A1 (en) * 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
ES2795818T3 (es) Anticuerpos CD48 y conjugados de los mismos
CN113710277B (zh) 一种负载双毒素的抗体药物偶联物及其应用
ES2955961T3 (es) Anticuerpos anti-ntb-a y composiciones y métodos relacionados
US11649286B2 (en) Tri-specific antibodies
Mountain et al. Engineering antibodies for therapy
AU2005218642B2 (en) Partially loaded antibodies and methods of their conjugation
CN101903403B (zh) Cd19结合剂及其应用
US6506881B1 (en) Anti-HMFG antibodies and processes for their production
WO2019108863A4 (en) Compositions and methods for the depletion of cd5+ cells
JP7799669B2 (ja) 抗体薬物コンジュゲート
JP2022530438A5 (cg-RX-API-DMAC7.html)
CN110352201A (zh) 用于癌症疗法的抗体药物缀合物的皮下施用
EP3958910A1 (en) Anti-cd45 antibody drug conjugates and uses thereof
JP2023520399A5 (cg-RX-API-DMAC7.html)
Mezzanzanica et al. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic
ES2528718T3 (es) Diana para linfocitos B
JP2023546293A5 (cg-RX-API-DMAC7.html)
JP2024540536A5 (cg-RX-API-DMAC7.html)
WO2017061602A1 (ja) Cd147分子に特異的に結合する抗体およびその利用
US20250339570A1 (en) Radioimmunoconjugates and therapeutic uses thereof
CANEVARI MARINA RIPAMONTI, FRANCISCO CONDE* and MARIA INES
KR20260022886A (ko) 방사성동위원소 표지된 cd25 표적 항체를 유효성분으로 포함하는 암의 방사면역치료용 약제학적 조성물
Kummer et al. Concepts of antibody-mediated cancer therapy
Makino et al. Expression of Tumor‐associated Glycoantigen, Sialyl Lewisa, in Human Head and Neck Squamous Cell Carcinoma and Its Application to Tumor Immunotherapy
Songsivilai et al. Bispecific monoclonal antibodies